Companies
Protix
Tyson Foods and Protix halted investment in a planned joint US insect-production facility in 2026, prompting Protix to redirect its international expansion focus toward Asia instead, where the company says it can be cost-competitive from day one.
- Country
- Netherlands
insect-lipid-protein
eu
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| food-alt-protein | — | ✓ | ✓ | ✓ |
| livestock-aqua | ✓ | ✓ | — | ✓ |
Regulatorsefsafdamoa-china
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | €55 million ($58.2 million) investment from Tyson Foods (2023-10-17) | globalpetindustry.com · raboinvestments.com · seafoodsource.com |
| Funding | €19 million convertible loan from existing shareholders (2025-08-01) | protein-trends.com · questionsforprotix.com |
| Funding | €1 million ($1.1 million) from Invest International for feasibility study (2025-01-01) | globalpetindustry.com · questionsforprotix.com |
| Funding | €50 million ($57.2 million) in equity (2022-01-01) | protix.com · seafoodsource.com |
| Capacity | 14,000 metric tons of live-larvae equivalent annually at Bergen op Zoom facility (2019-01-01) | protix.com · seafoodsource.com |
| Revenue | €11.8 million (2024-12-31) | protein-trends.com · questionsforprotix.com |
| Headcount | 150 full-time equivalents (2024-12-31) | protein-trends.com · questionsforprotix.com |
| Production site | Bergen op Zoom, Netherlands (operational since 2019) | agfundernews.com · protein-trends.com · raboinvestments.com · demolenaar.nl |
Independent sources: agfundernews.com · demolenaar.nl · globalpetindustry.com · protein-trends.com · raboinvestments.com · seafoodsource.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Alternative feeds for livestock | livestock-aqua | Medium | → |
| Industrial insect farming | food-alt-protein | High | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.